CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-11.33%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$742M
AUM Growth
+$742M
(-18%)
Cap. Flow
-$36.1M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
45.48%
Holding
92
New
8
Increased
13
Reduced
17
Closed
15
Top Buys
| 1 |
KA
Kineta, Inc. Common Stock
KA
|
$17.8M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$15.2M |
| 3 |
Theravance Biopharma
TBPH
|
$9.78M |
| 4 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
$9.14M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$7.99M |
Top Sells
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$23.4M |
| 2 |
MacroGenics
MGNX
|
$21.2M |
| 3 |
CLLS
Cellectis
CLLS
|
$12M |
| 4 |
ADXS
Advaxis, Inc.
ADXS
|
$9.85M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$8.55M |
Sector Composition
| 1 | Healthcare | 91.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KA
1
DELISTED
Kineta, Inc. Common Stock
KA
| $46.6M | 6.29% | 3,804,027 +1,454,027 | +62% | +$17.8M |
|
|
2
Theravance Biopharma
TBPH
$699M
| $45.4M | 6.12% | 1,425,000 +306,628 | +27% | +$9.78M |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $43.7M | 5.89% | 601,044 +110,000 | +22% | +$7.99M |
|
|
ALDR
4
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $32.9M | 4.43% | 1,581,604 -107,467 | -6% | -$2.24M |
|
|
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $32.5M | 4.38% | 410,000 -45,995 | -10% | -$3.65M |
|
6
Minerva Neurosciences
NERV
$16.5M
| $31.2M | 4.2% | 2,652,436 -147,564 | -5% | -$1.73M |
|
7
Ardelyx
ARDX
$1.53B
| $29.4M | 3.97% | 2,071,964 | – | – |
|
8
Aclaris Therapeutics
ACRS
$209M
| $26.5M | 3.57% | 976,286 +75,000 | +8% | +$2.04M |
|
9
Heron Therapeutics
HRTX
$207M
| $25.6M | 3.45% | 1,951,263 +180,000 | +10% | +$2.36M |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $23.6M | 3.18% | 841,752 +542,882 | +182% | +$15.2M |
|
11
Galapagos
GLPG
$2.07B
| $21.4M | 2.89% | 334,044 | – | – |
|
12
Corbus Pharmaceuticals
CRBP
$115M
| $21.1M | 2.85% | 2,500,000 +500,000 | +25% | +$4.23M |
|
13
Clearside Biomedical
CLSD
$28.9M
| $20.9M | 2.81% | 2,333,333 +345,125 | +17% | +$3.09M |
|
|
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $18.7M | 2.52% | 1,445,090 -160,700 | -10% | -$2.08M |
|
15
Protagonist Therapeutics
PTGX
$3.67B
| $15.8M | 2.13% | 720,000 -80,000 | -10% | -$1.76M |
|
16
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $14.6M | 1.97% | 519,090 -57,016 | -10% | -$1.6M |
|
|
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $14.2M | 1.92% | 2,940,000 +152,283 | +5% | +$737K |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $13.9M | 1.87% | 359,000 -39,301 | -10% | -$1.52M |
|
19
Wave Life Sciences
WVE
$1.53B
| $13.3M | 1.79% | 507,907 | – | – |
|
|
CBPO
20
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $12.1M | 1.64% | 112,867 | – | – |
|
|
PTLA
21
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $12.1M | 1.62% | 537,000 -59,000 | -10% | -$1.32M |
|
|
SYNH
22
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $10.5M | 1.42% | 200,000 | – | – |
|
|
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
| $10.1M | 1.36% | 1,150,000 | – | – |
|
24
Fulgent Genetics
FLGT
$679M
| $9.92M | 1.34% | 857,663 +57,663 | +7% | +$667K |
|
25
Omeros
OMER
$283M
| $9.67M | 1.3% | 975,000 -720,000 | -42% | -$7.14M |
|